Principal Investigator for the COAST study ( OPT-302 + Eylea) is Dr Charles Wykoff, MD PhD, Director of Research, Retina Consultants of Texas and Deputy Chair for Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Texas.
Principal Investigator for the ShORe study (OPT-302 + Lucentis) is Professor Tomothy Jackson, PhD, FRCOphth, consultant ophthalmic surgeon at King's College, London.
Dr Jason Slakter, founder and Director of the Digital Angiography Reading Center (DARC) in New York, and Clinical Professor of Ophthalmology at NYU School of Medicine, will also provide expertise as a leading authority on ocular imaging.
Principal Investigator for the COAST study ( OPT-302 + Eylea) is...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
63.0¢ |
Change
-0.010(1.56%) |
Mkt cap ! $775.5M | |||
| Open | High | Low | Value | Volume |
| 64.0¢ | 64.5¢ | 62.8¢ | $1.826M | 2.864M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3870 | 63.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 259093 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |